NovoCure Limited (NVCR)

Market Cap	1.27B
Revenue (ttm)	509.34M
Net Income (ttm)	-207.04M
Shares Out	107.09M
EPS (ttm)	-1.95
PE Ratio	n/a
Forward PE	909.09
Dividend	n/a
Ex-Dividend Date	n/a

Volume	742,576
Open	12.19
Previous Close	12.09
Day's Range	11.70 - 12.19
52-Week Range	10.87 - 83.60
Beta	0.43
Analysts	Buy
Price Target	45.89 (+287.91%)
Earnings Date	May 2, 2024

About NVCR

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporate...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 2, 2015
• Employees: 1,453
• Stock Exchange: NASDAQ
• Ticker Symbol: NVCR

Financial Performance

In 2023, NovoCure's revenue was $509.34 million, a decrease of -5.30% compared to the previous year's $537.84 million. Losses were -$207.04 million, 123.7% more than in 2022.

Analyst Forecast

According to 9 analysts, the average rating for NVCR stock is "Buy." The 12-month stock price forecast is $45.89, which is an increase of 287.91% from the latest price.

Price Target

$45.89

(287.91% upside)

Analyst Consensus: Buy